



Cornerstone Pharmaceuticals, Inc
1 Duncan Drive
Cranbury, NJ 08512

Media Contact: Meghan Weber
Liza Sullivan & Associates
(917) 399-8713

Cornerstone Pharmaceuticals Presents Interim Phase I Data at the European Society of Medical Oncology Annual Conference *Novel Therapeutic Targets and Attacks Cancer Metabolism*

MILAN Italy, October 11, 2010 – Cornerstone Pharmaceuticals, Inc., today presented new data highlighting the company’s novel approach to cancer drug development, which is based on targeting and disrupting the unique metabolic processes of cancer cells. These results were presented at the 35th European Society of Medical Oncology (ESMO) Congress. Cornerstone is a leader in the discovery and development of cancer therapies based on the science of cancer metabolism.

“Preliminary results from the ongoing Phase I study, demonstrate the safety of first-in-class agent, CPI-613, with very few adverse events, and the drug shows signs of efficacy in pancreatic and triple negative breast cancers,” said Dr. Robert Shepard, Chief Medical Officer for Cornerstone Pharmaceuticals.

Cornerstone’s lead drug candidate from its AEMD platform, CPI-613, is a first-in-class, small molecule drug. CPI-613 is currently being evaluated in three clinical trials, (i) a Phase I/II clinical study in cancer patients designed to determine its maximum tolerated dose, and evaluate its safety and efficacy, (ii) a Phase I/II trial evaluating CPI-613 in first-line treatment for pancreatic cancer in combination with Gemcitabine and (iii) a Phase I study evaluating CPI-613 in hematologic malignancies, including acute myelogenous leukemia (AML.)

To see the complete abstract of the study click here. (ADD LINK TO ABSTRACT) For more information about trials please contact: www.clinicaltrials.gov

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company’s founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. Cornerstone currently has a drug in clinical trials targeting certain key enzymes crucial to cancer cell metabolism. AEMD compounds, the company’s unique approach to cancer treatment, is the leading platform in cancer metabolism. It has facilitated the discovery of first-in-class drugs with the potential to transform the way cancer is treated. For further information, visit www.cornerstonepharma.com.

About CPI-613

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes considered to be common to many, if not all, cancer types and minimally functional in normal cells. Patients with solid tumors and hematologic cancers are currently being enrolled in multiple Phase I and Phase I/II human clinical trials evaluating CPI-613. These trials include a Phase I/II single agent trial for patients with solid tumors who have been failed by other therapy options, a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients, and a single agent trial in hematologic malignancies. CPI-613 was granted orphan drug status by the US FDA for pancreatic cancer, which has a poor prognosis, spreads rapidly and often goes undetected in its early stages.

About Cancer Metabolism

Cancer cell metabolism is an exciting and promising area for the development of drugs to treat cancer. While it has been known for nearly a century that cancer cells have a unique metabolism, only recently has there been a broad and significant renewal of scientific interest focused on exploring this unique metabolic difference to facilitate the discovery and development of groundbreaking therapies. Unlike normal cell metabolism, cancer cell metabolism utilizes less oxygen and has different nutritional requirements to survive and proliferate. This metabolic difference is considered to be fundamental to the transformation of normal cells into cancer cells and is believed to be conserved in all cancers, including solid tumors, lymphoma and leukemia. By better understanding these cancer-specific metabolic processes, researchers in the field hope to find new drugs to revolutionize cancer treatment.

#

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.